Current through Bulletin 2024-24, December 15, 2024
(1) Under Subsection
58-37f-203(1),
each pharmacy or pharmacy group shall submit the data required in this section
on a daily basis, either in real time or daily batch file reporting. The
submitted data shall be from the point of sale date.
(a) If the data is submitted by a single
pharmacy entity, the data shall be submitted in chronological order according
to the date each prescription was sold.
(b) If the data is submitted by a pharmacy
group, the data shall be sorted by individual pharmacy within the group, and
the data of each individual pharmacy within the group shall be submitted in
chronological order according to the date each prescription was sold.
(2) Under Subsections
58-37f-203(2), (3), and (6), the data required by this
section shall be submitted to the Database through one of the following
methods:
(a) electronic data sent via a
secured internet transfer method, including sFTP site transfer;
(b) secure web base service; or
(c) another electronic method approved by the
Database administrator prior to submission.
(3) Under Subsections
58-37f-203(2), (3), and (6), the format for submission to
the Database shall be Version 4.2 of the ASAP Format for Controlled Substances.
The Division may approve alternative formats substantially similar to this
standard.
(4) Under Subsection
58-37f-203(6),
the pharmacist-in-charge and the pharmacist identified in Subsections
58-37f-203(2) and (3) shall provide the following data
fields to the Division:
(a) version of ASAP
used to send transaction (ASAP 4.2 code TH01);
(b) transaction control number
(TH02);
(c) date transaction
created (TH05);
(d) time
transaction created (TH06);
(e)
file type (production or test) (TH07);
(f) segment terminator character
(TH09);
(g) information source
identification number (IS01);
(h)
information source entity name (IS02);
(i) reporting pharmacy's:
(i) National Provider Identifier (PHA01);
and
(ii) identifier assigned by
NCPDP or NABP (PHA02), or if none, then DEA registration number (PHA03);
(j) patient last name
(PAT07);
(k) patient first name
(PAT08);
(l) patient address
(PAT12);
(m) patient city of
residence (PAT14);
(n) patient zip
code (PAT 16);
(o) patient date of
birth (PAT18);
(p) dispensing
status - new, revised, or void (DSP01);
(q) prescription number (DSP02);
(r) date prescription written by prescriber
(DSP03);
(s) number of refills
authorized by prescriber (DSP04);
(t) date prescription filled at dispensing
pharmacy (DSP05);
(u) if current
dispensed prescription is a refill, the number of the refill being dispensed
(DSP06);
(v) product identification
qualifier (DSP07);
(w) NDC 11-digit
drug identification number (DSP08);
(x) quantity of drug dispensed in metric
units (DSP09);
(y) days supply
dispensed (DSP10);
(z) date drug
left the pharmacy, meaning date sold (DSP17);
(aa) DEA registration number of prescribing
practitioner (PRE02);
(bb) state
that issued identification of individual picking up dispensed drug
(AIR03);
(cc) type of
identification used by individual picking up dispensed drug (AIR04);
(dd) identification number of individual
picking up dispensed drug (AIR05);
(ee) last name of individual picking up
dispensed drug (AIR07);
(ff) first
name of individual picking up dispensed drug (AIR08);
(gg) dispensing pharmacist last name or
initial (AIR09);
(hh) dispensing
pharmacist first name (AIR10);
(ii)
number of detail segments included for the pharmacy (TP01);
(jj) transaction control number (TT01);
and
(kk) total number of segments
included in the transaction (TT02).
(5) Under Subsection
58-37f-203(6),
if no controlled substance required to be reported has been dispensed since the
previous submission of data, then the pharmacist-in-charge and the pharmacist
shall submit a zero report to the Division, which shall include the following
data fields:
(a) version of ASAP used to send
transaction (TH01);
(b) transaction
control number (TH02);
(c) date
transaction created (TH05);
(d)
time transaction created (TH06);
(e) file type (production or test)
(TH07);
(f) segment terminator
(TH09);
(g) information source
identification number (IS01);
(h)
information source entity name (IS02);
(i) date range (IS03);
(j) reporting pharmacy's:
(i) National Provider Identifier (PHA01); and
(ii) identifier assigned by NCPDB
or NABP (PHA02), or if none, then DEA registration number
(PHA03);
(k) patient last
name = "Report" (PAT07);
(l) patient
first name = "Zero" (PAT08);
(m)
date prescription dispensed at dispensing pharmacy (DSP05);
(n) number of detail segments included for
the pharmacy (TP01);
(o)
transaction control number (TT01); and
(p) total number of segments included in the
transaction (TT02).
(6)
Under Subsection
58-37f-203(2),
a Class A, B, D, or E pharmacy or pharmacy group that has a controlled
substance license but is not dispensing controlled substances and does not
anticipate doing so in the immediate future may request a waiver or submit a
certification, in a form preapproved by the Division, in lieu of daily zero
reports:
(a) The pharmacy or pharmacy group
shall renew its waiver or certification at the end of each calendar
year.
(b) If a pharmacy or pharmacy
group with a current waiver or certification dispenses a controlled substance:
(i) the waiver or certification shall
immediately and automatically terminate;
(ii) the Database reporting requirements of
Subsections
58-37f-203(1) and R156-37f-203(1) shall apply to the pharmacy or pharmacy group immediately
upon the dispensing of the controlled substance; and
(iii) the pharmacy or pharmacy group shall
notify the Division in writing of the waiver or certification termination
within 24 hours or the next business day of the dispensing of the controlled
substance, whichever is later.
(7) The Database shall collect information
regarding the prescription noncontrolled substance
1-(Aminomethyl)-cyclohexaneacetic acid (Gabapentin), in accordance with
Subsection
58-37f-203(8).
(8) The Database shall collect information
regarding "any substance which contains any quantity of a derivative of
barbituric acid or any salt of any of them" (Butalbital), in accordance with
Subsection
58-37-4(2)(c)(ii) which designates this as a Schedule III controlled
substance.
